Search results for CHD4 antibody

Anti-CHD4 antibody [BLR066G], Abcam, AB264417

REACH authorisation Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances. It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses. This product is sold under License from Bethyl Laboratories, Inc.

Anti-CHD4 antibody [EPR12229], Abcam, AB181370

Species reactivity Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

CHD4 antibody [5F1-A11-C9], Genetex, GTX49139

PE Anti-CHD4 antibody [EPR12229], Abcam, AB305538

This conjugated primary antibody is "made to order" and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link ® conjugation technology , Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

APC Anti-CHD4 antibody [EPR12229], Abcam, AB305539

This conjugated primary antibody is "made to order" and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link ® conjugation technology , Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Anti-CHD4 antibody [3F2/4], Abcam, AB70469

Want a custom formulation? This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact [email protected]

Anti-CHD4 antibody [EPR29845-521], Abcam, AB324561

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Purified anti-CHD4 Antibody, CHD4, W18333A, BioLegend, 942301

During product development testing for western blot, we observed additional bands below the predominant, full-length CHD4 band. These additional bands were also detected using a CHD4 antibody raised using a separate immunogen. We therefore believe these bands represent CHD4 degradation products or additional CHD4 isoforms.This clone was tested for ICC using 4% PFA-fixed HeLa cells permeabilized with either Triton X-100 or methanol. While both methods were compatible with robust CHD4 staining, we observed punctate, extranuclear staining of cells permeabilzed with Triton X-100. We therefore do not recommend this method when using the clone for ICC.

Purified anti-CHD4 Antibody, CHD4, W18333A, BioLegend, 942302

During product development testing for western blot, we observed additional bands below the predominant, full-length CHD4 band. These additional bands were also detected using a CHD4 antibody raised using a separate immunogen. We therefore believe these bands represent CHD4 degradation products or additional CHD4 isoforms.This clone was tested for ICC using 4% PFA-fixed HeLa cells permeabilized with either Triton X-100 or methanol. While both methods were compatible with robust CHD4 staining, we observed punctate, extranuclear staining of cells permeabilzed with Triton X-100. We therefore do not recommend this method when using the clone for ICC.

Anti-CHD4 antibody [EPR12229] - BSA and Azide free, Abcam, AB250495

ab250495 is the carrier-free version of ab181370 . Species reactivity Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Conjugation ready Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications. Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold. Compatibility This product is compatible with the Maxpar ® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar ® is a trademark of Fluidigm Canada Inc.